Advertisement

Tumor Biology

, Volume 36, Issue 12, pp 9895–9901 | Cite as

miR-141 as potential suppressor of β-catenin in breast cancer

  • Nairi Abedi
  • Samira Mohammadi-Yeganeh
  • Ameneh Koochaki
  • Fariba Karami
  • Mahdi Paryan
Research Article

Abstract

Triple negative breast cancer (TNBC) is well known for its heterogeneous features and lack of targeted therapy. A variety of cell signaling pathways have been linked to the initiation and progression of these tumors where canonical Wnt signaling is one of the main candidate pathways. Considering past literatures on this matter and negative reports regarding mutations in β-catenin gene (CTNNB1), we focus our attention to another level of gene expression control level, microRNAs (miRNAs). For proper miRNA target detection, we utilized bioinformatics as a relatively new and reliable tool for miRNA: mRNA prediction. MDA-MB-231 (invasive breast cancer) and MCF-10A (normal breast) cell lines were chosen as models. We used different bioinformatic tools such as TargetScan, miRanda, etc. For miRNA targeting CTNNB1-3´UTR confirmation, luciferase assay was carried out. miRNA expression was induced in cell lines through viral constructs expressing desired miRNA. Quantitative real-time PCR was performed for the measurement of expression levels of selected miRNA and target gene. miR-141 was selected via expanded search among various bioinformatic tools. miR-141 expression level was downregulated in MDA-MB-231 cell line, and CTNNB1 gene expression was upregulated. After transduction with viral construct, miR-141 expression was elevated in both cell lines, and gene expression was notably decreased. β-Catenin can be considered as one of the main players in these tumors’ pathogenesis. Also, it is the potential target of miR-141, in which its downregulation was detected in cell lines, and can be considered as a promising new targeted approach toward TNBC.

Keywords

Triple negative breast cancer Wnt signaling miRNA CTNNB1 gene Luciferase assay 

Notes

Acknowledgments

This work was funded by Pasteur Institute of Iran, Tehran. The authors appreciate Stem Cell Technology Research Center, Tehran, Iran, and also Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences,Tehran, Iran for providing technical support. The authors would like to thank Mr. Vahid Kia for final proofreading of the manuscript.

Conflicts of interest

None

References

  1. 1.
    Singh R, Mo Y-Y. Role of microRNAs in breast cancer. Cancer Biol Ther. 2013;14(3):201–12.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Shah NR, Chen H. MicroRNAs in pathogenesis of breast cancer: implications in diagnosis and treatment. World J Clin Oncol. 2014;5(2):48.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Avery-Kiejda KA et al. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer. 2014;14(1):51.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gasparini P et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014;5(5):1174.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Schneider BP et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Kamdje AHN et al. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. 2014;26(12):2843–56.CrossRefGoogle Scholar
  7. 7.
    Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther. 2004;3(1):36–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Chu EY et al. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development. 2004;131(19):4819–29.CrossRefPubMedGoogle Scholar
  9. 9.
    Khramtsov AI et al. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176(6):2911–20.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hatsell S et al. β-Catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2003;8(2):145–58.CrossRefPubMedGoogle Scholar
  11. 11.
    Cai J et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest. 2013;123(2):566.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126–39.CrossRefPubMedGoogle Scholar
  13. 13.
    Cai Y et al. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7(4):147–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Winter J et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228–34.CrossRefPubMedGoogle Scholar
  15. 15.
    Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66(15):7390–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Nana-Sinkam SP, Fabbri M, Croce CM. MicroRNAs in cancer: personalizing diagnosis and therapy. Ann N Y Acad Sci. 2010;1210(1):25–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Faryal R. Role of miRNAs in breast cancer. Asian Pac J Cancer Prev. 2011;12:3175–80.PubMedGoogle Scholar
  18. 18.
    Mendes N, Freitas AT, Sagot M-F. Current tools for the identification of miRNA genes and their targets. Nucleic Acids Res. 2009;37(8):2419–33.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Al-Rajab M. and J. Lu, Bioinformatics: an overview for cancer research. 2012.Google Scholar
  20. 20.
    Mount, D.W., Sequence and genome analysis. Bioinformatics: Cold Spring Harbour Laboratory Press: Cold Spring Harbour. 2004; 2.Google Scholar
  21. 21.
    Dull T et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–71.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Huang K et al. MicroRNA roles in beta-catenin pathway. Mol Cancer. 2010;9(1):252.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhao H et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One. 2010;5(10), e13735.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Xin F et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics. 2009;25(4):430–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang C et al. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31(1):58.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mohammadi-Yeganeh S et al. Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis. Mol Biol Rep. 2013;40(5):3665–74.CrossRefPubMedGoogle Scholar
  27. 27.
    Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 2013;11(1):280.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Esau C et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem. 2004;279(50):52361–5.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of New Sciences, Tehran Medical BranchIslamic Azad UniversityTehranIran
  2. 2.Cellular and Molecular Biology Research CenterShahid Beheshti University of Medical SciencesTehranIran
  3. 3.Department of Biotechnology, School of Advanced Technologies in MedicineShahid Beheshti University of Medical SciencesTehranIran
  4. 4.Department of Research and Development, Production and Research ComplexPasteur Institute of IranTehranIran

Personalised recommendations